主要文件

查看所有文档

L6292

赖诺普利

Name: 赖诺普利
Brand: SIGMA

≥98% (HPLC), Angiotensin converting enzyme (ACE) inhibitor., solid

别名:

MK-521, （S）-1- [N2-（1-羧基-3-苯丙基）-赖氨酰脯氨酸二水合物

登录查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:

C₂₁H₃₁O₅N₃ · 2H₂O

化学文摘社编号:

83915-83-7

分子量:

441.52

UNSPSC Code:

12352200

PubChem Substance ID:

329817636

NACRES:

NA.32

MDL number:

MFCD01698825

Assay:

≥98% (HPLC)

Form:

solid

Quality level:

100

技术服务

需要帮助？我们经验丰富的科学家团队随时乐意为您服务。

让我们为您提供帮助

属性

产品名称

赖诺普利, ≥98% (HPLC)

Quality Level

100

assay

≥98% (HPLC)

form

solid

color

white

solubility

H₂O: ≥10 mg/mL, DMSO: ~6.5 mg/mL (with heating and sonicating)

storage temp.

2-8°C

SMILES string

[H]O[H].[H]O[H].NCCCC[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N2CCC[C@H]2C(O)=O

InChI

1S/C21H31N3O5.2H2O/c22-13-5-4-9-16(19(25)24-14-6-10-18(24)21(28)29)23-17(20(26)27)12-11-15-7-2-1-3-8-15;;/h1-3,7-8,16-18,23H,4-6,9-14,22H2,(H,26,27)(H,28,29);2*1H2/t16-,17-,18-;;/m0../s1

InChI key

CZRQXSDBMCMPNJ-ZUIPZQNBSA-N

Gene Information

human ... ACE(1636)

说明

Application

赖诺普利已被用于研究杜氏营养不良症小鼠的抗纤维化作用。它已被用于研究经过长期达贝泊汀处理后的 TGR（mRen2）27 （携带小鼠 Ren-2 基因的转基因大鼠）大鼠的肾结构和功能的变化。

Biochem/physiol Actions

血管紧张素转换酶（ACE）抑制剂。

Features and Benefits

该化合物是位于美国新泽西Kenilworth的Merck & Co., Inc.开发。想要浏览其他由制药公司开发的化合物以及已批准药物/候选药物清单，请单击此处。

Still not finding the right product?

Explore all of our products under 赖诺普利

pictograms

GHS08

signalword

Danger

hcodes

H360D,H373

pcodes

P202 - P260 - P280 - P308 + P313 - P405 - P501

Hazard Classifications

Repr. 1A - STOT RE 2

target_organs

Kidney

存储类别

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Renal effects of long-term darbepoetin alpha treatment in hypertensive TGR(mRen2)27 rats.

Anne-Roos S Frenay et al.

Journal of the renin-angiotensin-aldosterone system : JRAAS, 13(2), 232-238 (2012-01-28)

Erytropoietin (EPO) has cytoprotective and angiogenic properties and has a beneficial effect in ischaemic conditions. Since the development of renal interstitial abnormalities are often associated with ischaemia, we studied the effects of the long-acting EPO analogue darbepoetin alpha (DA) on

Angiotensin converting enzyme inhibitor and HMG-CoA reductase inhibitor as adjunct treatment for persons with HIV infection: a feasibility randomized trial.

Jason V Baker et al.

PloS one, 7(10), e46894-e46894 (2012-10-20)

Treatments that reduce inflammation and cardiovascular disease (CVD) risk among individuals with HIV infection receiving effective antiretroviral therapy (ART) are needed. We conducted a 2 × 2 factorial feasibility study of lisinopril (L) (10 mg daily) vs L-placebo in combination

Epidermal growth factor receptor inhibitor PKI-166 governs cardiovascular protection without beneficial effects on the kidney in hypertensive 5/6 nephrectomized rats.

Nadir Ulu et al.

The Journal of pharmacology and experimental therapeutics, 345(3), 393-403 (2013-03-27)

Transactivation of epidermal growth factor receptor (EGFR) signaling by G protein-coupled receptors has been implicated in several cardiovascular (CV) conditions, including hypertension, heart failure, and cardiac and vascular hypertrophy. However, the therapeutic potential of EGFR inhibition in these conditions is

查看所有相关文献

全球贸易项目编号

货号	GTIN
L6292-250MG	04061833026496
L6292-100MG	04061833958711